CVR number 10042569
Industry 46.4620 Wholesale of pharmaceutical goods

EKKOMED A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  4.5% 2.2% 2.7% 2.1% 2.1%  
Credit score (0-100)  47 64 60 66 67  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.1 0.0 0.2 0.2  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  9,392 3,209 4,925 4,531 4,257  
EBITDA  6,830 858 2,279 1,610 1,458  
EBIT  6,826 854 2,274 1,603 1,453  
Pre-tax profit (PTP)  6,619.7 840.1 2,115.9 1,559.9 1,404.5  
Net earnings  5,160.9 651.2 1,649.4 1,213.6 1,095.5  
Pre-tax profit without non-rec. items  6,620 840 2,116 1,560 1,405  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  8.4 4.9 40.5 34.0 29.0  
Shareholders equity total  6,499 2,150 3,150 2,763 2,659  
Interest-bearing liabilities  0.0 432 160 189 217  
Balance sheet total (assets)  9,380 3,857 5,168 4,704 4,289  
Net Debt  -5,840 -507 -718 -559 -872  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  9,392 3,209 4,925 4,531 4,257  
Gross profit growth  149.8% -65.8% 53.4% -8.0% -6.0%  
Employees  7 7 7 7 7  
Employee growth %  16.7% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  9,380 3,857 5,168 4,704 4,289  
Balance sheet change%  142.5% -58.9% 34.0% -9.0% -8.8%  
Added value  6,829.5 857.7 2,279.1 1,608.3 1,458.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -7 -7 31 -13 -10  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  72.7% 26.6% 46.2% 35.4% 34.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  103.2% 13.5% 50.4% 32.8% 32.4%  
ROI %  154.6% 19.6% 77.2% 51.7% 50.0%  
ROE %  116.8% 15.1% 62.2% 41.0% 40.4%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  69.3% 55.7% 61.0% 58.7% 62.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -85.5% -59.1% -31.5% -34.7% -59.8%  
Gearing %  0.0% 20.1% 5.1% 6.9% 8.1%  
Net interest  0 0 0 0 0  
Financing costs %  56,125.3% 24.0% 53.5% 33.7% 26.5%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  2.6 1.3 1.3 1.2 1.4  
Current Ratio  3.2 2.3 2.5 2.4 2.6  
Cash and cash equivalent  5,840.3 938.9 877.8 748.9 1,089.1  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  6,392.1 2,132.1 3,010.7 2,631.1 2,532.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  976 123 326 230 208  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  976 123 326 230 208  
EBIT / employee  975 122 325 229 208  
Net earnings / employee  737 93 236 173 157